For IV formulation it is as advanced as the melanoma work.
In many presentations for biotechs this stage is broadly referred to as "IND-enabling".
It might be that they are not far off achieving a stage suitable for IV-administration to be trialled in Australia or in the US. Maybe a small two-stratum Phase 1 trial comparing central line and IV administration?
RAC Price at posting:
$3.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)